Stalicla develops precision-medicine therapeutics for neurodevelopmental and neuropsychiatric disorders. Its lead autism candidate, STP1, is slated to enter Phase 2 trials, and the company has a second autism-targeted asset aimed at a distinct ASD patient subgroup. Stalicla is also advancing STP7 (mavoglurant), an mGluR5 negative allosteric modulator, for cocaine use disorder under a CRADA with NIDA at the NIH; that program is described as the most advanced treatment candidate for that indication. The company recently secured a CHF 2 million investment led by Addex to fund program advancement, asset partnering, preparation for a Series C financing, and general corporate purposes. As part of the investment, Addex’s CEO was named to Stalicla’s board and nominated as chairman.

Total raised

$28M

Funding rounds

4

Latest round

Equity

Latest activity

Mar 2026